Hvivo results Q&A with CEO Mo Khan: “we are very confident we will get to £100m of revenue in 2028”
Episode 1843, Apr 09, 08:36 AM
Watch on YouTube
After another record year for human challenge specialist Hvivo, chief executive Mo Khan talks us through the building blocks he’s putting in place to take the company to its longer-term target of £100m of sales by 2028.
0:30 Highlights of 2023 results, including record revenues and profitability, and Ebitda margins ahead of guidance.
1:30 Headwinds from MHRA review delays offset by client funding for new Canary Wharf facility.
2:20 What’s driving strong cash generation, and plans for regular shareholder returns.
3:40 Progress at the new Canary Wharf facility and government backing for a life science hub in the area.
6:40 How 2024 is shaping up, and how an increasingly diversified client base is improving resilience.
8:42 How the business is going to reach its longer term £200m sales target, including more human challenge models and M&A.
10:20 The value of recent attendance of the World Vaccine Congress Washington.
After another record year for human challenge specialist Hvivo, chief executive Mo Khan talks us through the building blocks he’s putting in place to take the company to its longer-term target of £100m of sales by 2028.
0:30 Highlights of 2023 results, including record revenues and profitability, and Ebitda margins ahead of guidance.
1:30 Headwinds from MHRA review delays offset by client funding for new Canary Wharf facility.
2:20 What’s driving strong cash generation, and plans for regular shareholder returns.
3:40 Progress at the new Canary Wharf facility and government backing for a life science hub in the area.
6:40 How 2024 is shaping up, and how an increasingly diversified client base is improving resilience.
8:42 How the business is going to reach its longer term £200m sales target, including more human challenge models and M&A.
10:20 The value of recent attendance of the World Vaccine Congress Washington.